Mymetics Corp (MYMX)

[bow-tie]

CATALENT
Is My Molecule Suitable for an Orally Disintegrating Tablet?

A panel of four speakers will review the fundamentals of ODTs, including benefits, formats and development pathways, contrast with other oral dose forms, outline likely drug candidates and discuss Catalent’s proprietary ZYDIS® lyophilized ODT platform. The panel will further address the unique delivery routes associated with ODTs, including the potential for pre-gastric or gastrointestinal delivery and local activity at the oral mucosa, and review the physicochemical characteristics appropriate for each.

https://www.catalent.com/expert-content/oral-technologies/is-my-molecule-suitable-for-an-orally-disintegrating-tablet/